چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | اسرا سادات طالبی زنوزی |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | دانشکده پزشکی |
| کد مقاله | 87574 |
| عنوان فارسی مقاله | ارزیابی دوز تابشی و ریسک القای سرطان در رادیوایمبولیزاسیون با هولمیوم-166 و ایتریوم-90 |
| عنوان لاتین مقاله | Assessment of radiation dose and radiation-induced cancer risk in Ho-166 and Y-90 radioembolization |
| نوع ارائه | پوستر |
| عنوان کنگره / همایش | نهمین کنگره بین المللی و نوزدهمین کنگره سالیانه کلینیکال انکولوژی |
| نوع کنگره / همایش | بین المللی |
| کشور محل برگزاری کنگره/ همایش | Iran (Islamic Republic) |
| شهر محل برگزاری کنگره/ همایش | تهران |
| سال انتشار/ ارائه شمسی | 1403 |
| سال انتشار/ارائه میلادی | 2025 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1403/11/10 الی 1403/11/12 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | https://iscocongress.com/ |
| آدرس علمی (Affiliation) نویسنده متقاضی | Department of Medical Physics, Tabriz University of Medical Sciences, Tabriz, Iran |
| نویسنده | نفر چندم مقاله |
|---|---|
| اسرا سادات طالبی زنوزی | اول |
| رقیه بداقی حسین ابادی | دوم |
| عنوان | متن |
|---|---|
| کلمات کلیدی | radioembolization, Y-90, Ho-166, monte Carlo, Lifetime Attributable Risk |
| خلاصه مقاله | Background: Transarterial radioembolization (TARE) serves as a palliative measure for both primary and metastatic liver malignancies. This minimally invasive procedure delivers radiation directly to the tumor via tiny radioactive beads, offering symptom relief and potentially slowing disease progression. Currently, Y-90 and Ho-166 are utilized in TARE, representing two key radioactive isotopes employed for this procedure. Objective: This study aims to evaluate and compare the radiation doses as well as the associated risks of cancer induction between Y-90 and Ho-166 TARE. Methods: The study utilized Gate 9.2 Monte Carlo toolkit in conjunction with ICRP110 voxelized phantom. A tumor with a diameter of 3 cm was modelled within the liver, with Y-90 and Ho-166 uniformly distributed within the tumor. Absorbed doses in phantom organs were calculated. Employing the biological effects of ionizing radiation (BEIR VII) report, the Lifetime Attributable Risk (LAR) of cancer incidence and mortality was computed. Results: In Y-90 TARE, the mean absorbed doses for tumoral liver tissue, non-tumoral liver tissue, stomach, lung and bladder are 3.36, 0.003, 3.66 ×10-6, 5 ×10-7 and 0.001 Gy/MBq, respectively. In Ho-166 TARE, these values for tumoral liver tissue, non-tumoral liver tissue, stomach, lung and bladder are 0.466, 0.271, 2.46 × 10-5, 1.66 × 10-5 and 6.07 ×10-5 Gy/MBq, respectively. The mean cancer incidence risks per 100,000 people were 1.5 and 10.2 for Y-90 TARE and Ho-166 TARE, respectively. For Y-90 TARE and Ho-166 TARE, the mean LAR of cancer mortality for all cancer was 0.52 and 3.36, respectively, per 100,000 people. Conclusion: The radiation-induced cancer risk in Ho-166 TARE is significantly higher Y-90 TARE. Consequently, Ho-166 TARE is associated with a noteworthy risk of cancer induction, underscoring the importance of optimizing patient radiation doses to mitigate this risk. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| Untitled1.pdf | 1404/02/16 | 287593 | دانلود |
| Certificate Poster.pdf | 1404/02/16 | 190542 | دانلود |
